Oncogenic ERBB3 Mutations in Human Cancers

Cancer Cell

Volumn 23, Issue 5, 2013, Pages 603-617

  Jaiswal, BijayS ^a   Kljavin, NoelynM ^a   Stawiski, EricW ^a,b   Chan, Emily ^a   Parikh, Chaitali ^a   Durinck, Steffen ^a,b   Chaudhuri, Subhra ^a   Pujara, Kanan ^a   Guillory, Joseph ^a   Edgar, KyleA ^a   Janakiraman, Vasantharajan ^a   Scholz, Rolf Peter ^c   Bowman, KristaK ^a   Lorenzo, Maria ^a   Li, Hong ^a   Wu, Jiansheng ^a   Yuan, Wenlin ^a   Peters, BrockA ^a   Kan, Zhengyan ^a   Stinson, Jeremy ^a   Mak, Michelle ^a   Modrusan, Zora ^a   Eigenbrot, Charles ^a   Firestein, Ron ^a   Stern, HowardM ^a   Rajalingam, Krishnaraj ^c   Schaefer, Gabriele ^a   Merchant, MarkA ^a   Sliwkowski, MarkX ^a   deSauvage, FredericJ ^a   Seshagiri, Somasekar ^a   more..

^a Department of Molecular Biology ^*  (United States)

^b GENENTECH INC   (United States)

^c GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CARCINOGENESIS; COLON CANCER; COLON MUCOSA; DISEASE COURSE; ENZYME ACTIVITY; EPITHELIUM CELL; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SOMATIC MUTATION; STOMACH CANCER;

EID: 84877839648     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.04.012     Document Type: Article

References (63)

1. Alvarado D., Klein D.E., Lemmon M.A. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor. Nature 2009, 461:287-291.
2. Alvarez R.H., Valero V., Hortobagyi G.N. Emerging targeted therapies for breast cancer. J.Clin. Oncol. 2010, 28:3366-3379.
3. Amin D.N., Campbell M.R., Moasser M.M. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin. Cell Dev. Biol. 2010, 21:944-950.
4. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9:463-475.
5. Brummer T., Schramek D., Hayes V.M., Bennett H.L., Caldon C.E., Musgrove E.A., Daly R.J. Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. J.Biol. Chem. 2006, 281:626-637.
6. Bundy L., Wells S., Sealy L. C/EBPbeta-2 confers EGF-independent growth and disrupts the normal acinar architecture of human mammary epithelial cells. Mol. Cancer 2005, 4:43.
7. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P., Leahy D.J., Lemmon M.A., Sliwkowski M.X., Ward C.W., Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 2003, 12:541-552.
8. Cho H.S., Leahy D.J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002, 297:1330-1333.
9. D'Abaco G.M., Whitehead R.H., Burgess A.W. Synergy between Apc min and an activated ras mutation is sufficient to induce colon carcinomas. Mol. Cell. Biol. 1996, 16:884-891.
10. Dawson J.P., Berger M.B., Lin C.C., Schlessinger J., Lemmon M.A., Ferguson K.M. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol. Cell. Biol. 2005, 25:7734-7742.
11. Debnath J., Walker S.J., Brugge J.S. Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. J.Cell Biol. 2003, 163:315-326.
12. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
13. Edgar K.A., Wallin J.J., Berry M., Lee L.B., Prior W.W., Sampath D., Friedman L.S., Belvin M. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res. 2010, 70:1164-1172.
14. Ferguson K.M. Structure-based view of epidermal growth factor receptor regulation. Annu. Rev. Biophys. 2008, 37:353-373.
15. Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.S., Leahy D.J., Lemmon M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 2003, 11:507-517.
16. Garnett M.J., Edelman E.J., Heidorn S.J., Greenman C.D., Dastur A., Lau K.W., Greninger P., Thompson I.R., Luo X., Soares J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
17. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Kofler M., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 2003, 11:495-505.
18. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
19. Hegde G.V., de la Cruz C.C., Chiu C., Alag N., Schaefer G., Crocker L., Ross S., Goldenberg D., Merchant M., Tien J., et al. Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci. Transl. Med. 2013, 5:171ra18.
20. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 2003, 100:8933-8938.
21. Horn S., Bergholz U., Jücker M., McCubrey J.A., Trümper L., Stocking C., Bäsecke J. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. Oncogene 2008, 27:4096-4106.
22. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
23. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 2009, 21:177-184.
24. Jaiswal B.S., Janakiraman V., Kljavin N.M., Chaudhuri S., Stern H.M., Wang W., Kan Z., Dbouk H.A., Peters B.A., Waring P., et al. Somatic mutations in p85α promote tumorigenesis through class IA PI3K activation. Cancer Cell 2009, 16:463-474.
25. Jeong E.G., Soung Y.H., Lee J.W., Lee S.H., Nam S.W., Lee J.Y., Yoo N.J., Lee S.H. ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. Int. J. Cancer 2006, 119:2986-2987.
26. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., Sampath D., Sliwkowski M.X. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440.
27. Jura N., Shan Y., Cao X., Shaw D.E., Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl. Acad. Sci. USA 2009, 106:21608-21613.
28. Kan Z., Jaiswal B.S., Stinson J., Janakiraman V., Bhatt D., Stern H.M., Yue P., Haverty P.M., Bourgon R., Zheng J., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466:869-873.
29. Karunagaran D., Tzahar E., Beerli R.R., Chen X., Graus-Porta D., Ratzkin B.J., Seger R., Hynes N.E., Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 1996, 15:254-264.
30. Koutras A.K., Fountzilas G., Kalogeras K.T., Starakis I., Iconomou G., Kalofonos H.P. The upgraded role of HER3 and HER4 receptors in breast cancer. Crit. Rev. Oncol. Hematol. 2010, 74:73-78.
31. Lee J.C., Vivanco I., Beroukhim R., Huang J.H., Feng W.L., DeBiasi R.M., Yoshimoto K., King J.C., Nghiemphu P., Yuza Y., et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006, 3:e485.
32. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., Sliwkowski M.X., Stern H.M. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008, 68:5878-5887.
33. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
34. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J.W., Kussie P., Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.
35. Medina P.J., Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther. 2008, 30:1426-1447.
36. Muthuswamy S.K. 3D culture reveals a signaling network. Breast Cancer Res. 2011, 13:103.
37. Muthuswamy S.K., Li D., Lelievre S., Bissell M.J., Brugge J.S. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat. Cell Biol. 2001, 3:785-792.
38. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110:775-787.
39. Petersen O.W., Rønnov-Jessen L., Howlett A.R., Bissell M.J. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc. Natl. Acad. Sci. USA 1992, 89:9064-9068.
40. Pinkas-Kramarski R., Soussan L., Waterman H., Levkowitz G., Alroy I., Klapper L., Lavi S., Seger R., Ratzkin B.J., Sela M., Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996, 15:2452-2467.
41. Prickett T.D., Agrawal N.S., Wei X., Yates K.E., Lin J.C., Wunderlich J.R., Cronin J.C., Cruz P., Rosenberg S.A., Samuels Y. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 2009, 41:1127-1132.
42. Schaefer G., Haber L., Crocker L.M., Shia S., Shao L., Dowbenko D., Totpal K., Wong A., Lee C.V., Stawicki S., et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011, 20:472-486.
43. Seshagiri S., Stawiski E.W., Durinck S., Modrusan Z., Storm E.E., Conboy C.B., Chaudhuri S., Guan Y., Janakiraman V., Jaiswal B.S., et al. Recurrent R-spondin fusions in colon cancer. Nature 2012, 488:660-664.
44. Shi F., Telesco S.E., Liu Y., Radhakrishnan R., Lemmon M.A. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. USA 2010, 107:7692-7697.
45. Sithanandam G., Anderson L.M. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008, 15:413-448.
46. Sliwkowski M.X., Schaefer G., Akita R.W., Lofgren J.A., Fitzpatrick V.D., Nuijens A., Fendly B.M., Cerione R.A., Vandlen R.L., Carraway K.L. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J.Biol. Chem. 1994, 269:14661-14665.
47. Söderberg O., Gullberg M., Jarvius M., Ridderstråle K., Leuchowius K.J., Jarvius J., Wester K., Hydbring P., Bahram F., Larsson L.G., Landegren U. Direct observation of individual endogenous protein complexes insitu by proximity ligation. Nat. Methods 2006, 3:995-1000.
48. Soule H.D., Maloney T.M., Wolman S.R., Peterson W.D., Brenz R., McGrath C.M., Russo J., Pauley R.J., Jones R.F., Brooks S.C. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990, 50:6075-6086.
49. Stephens P.J., Tarpey P.S., Davies H., Van Loo P., Greenman C., Wedge D.C., Nik-Zainal S., Martin S., Varela I., Bignell G.R., et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486:400-404. Oslo Breast Cancer Consortium (OSBREAC).
50. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., Kryukov G.V., Lawrence M.S., Sougnez C., McKenna A., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
51. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. TCGA Cancer Genome Atlas Research Network.
52. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. TCGA Cancer Genome Atlas Research Network.
53. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. TCGA Cancer Genome Atlas Network.
54. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. TCGA Cancer Genome Atlas Network.
55. Thompson N., Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr. Opin. Pharmacol. 2005, 5:350-356.
56. Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., Ratzkin B.J., Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 1996, 16:5276-5287.
57. Wang S.E., Narasanna A., Perez-Torres M., Xiang B., Wu F.Y., Yang S., Carpenter G., Gazdar A.F., Muthuswamy S.K., Arteaga C.L. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10:25-38.
58. Wang K., Kan J., Yuen S.T., Shi S.T., Chu K.M., Law S., Chan T.L., Kan Z., Chan A.S., Tsui W.Y., et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 2011, 43:1219-1223.
59. Warmuth M., Kim S., Gu X.J., Xia G., Adrián F. Ba/F3 cells and their use in kinase drug discovery. Curr. Opin. Oncol. 2007, 19:55-60.
60. Whitehead R.H., VanEeden P.E., Noble M.D., Ataliotis P., Jat P.S. Establishment of conditionally immortalized epithelial cell lines from both colon and small intestine of adult H-2Kb-tsA58 transgenic mice. Proc. Natl. Acad. Sci. USA 1993, 90:587-591.
61. Wilson T.R., Lee D.Y., Berry L., Shames D.S., Settleman J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011, 20:158-172.
62. Yamauchi M., Gotoh N. Theme: oncology-molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates. Biomark. Med. 2009, 3:139-151.
63. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.